Please assess the completion status of the following clinical trial:

Trial Title: WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Known pathologically-confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin),~2. Confirmed symptomatic or incidental deep vein thrombosis requiring treatment, or confirmed symptomatic or incidental pulmonary embolism of a segmental or larger pulmonary artery,~3. Weight \> 90 kg,~4. Age ≥18 years,~5. Hemoglobin ≥ 80 g/L,~6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form.~Exclusion Criteria:~1. Acute VTE managed with thrombectomy, insertion of an inferior vena cava filter or with the use of thrombolytic agents,~2. More than 72 hours pre-treatment with therapeutic dosage of other LMWH, direct oral anticoagulants or vitamin K antagonists prior to enrolment to manage the current VTE event (unless the participant has been treated with weight-adjusted doses of commercial dalteparin in consistency with the dosing regime outlined in the protocol up to Day 7 visit \[±2 days\]),~3. Contraindication to heparin therapy:~   1. history of heparin induced thrombocytopenia (HIT) as reported by patient,~  2. platelet count of less than 50 x 109/L,~  3. actively bleeding,~  4. reported history of severe uncontrolled hypertension,~  5. documented peptic ulcer within 6 weeks,~  6. reported history of severe hepatic failure,~  7. creatinine clearance of \< 30 ml/min as calculated by the Cockcroft-Gault formula,~  8. heparin allergy,~  9. Other contraindication to anticoagulation.~4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at the time of study enrolment,~5. Life expectancy \< 1 month,~6. Women of childbearing age without proper contraceptive measures and women who are pregnant or breast feeding,~7. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor),~8. Unable/unwilling to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weight adjusted dalteparin (Type: EXPERIMENTAL): Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues